

REMARKSSpecification

The amendment and response submitted on July 19, 2004 contained a typographical error on page 3, incorrectly inserting the above listed paragraph page 11 of instead of page 10 of the substituted specification. Applicants herewith note that the specification has been amended, as listed above, to insert the amended paragraph on page 10 and remove the paragraph entered on page 11 in the prior amendment.

Conclusion

Applicants believe the application is now in condition for allowance. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: July 26, 2004

Reena R. Desai

Reena R. Desai
Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (619) 622-3087
Fax: (619) 678-8233